Comparing The Efficacy Of An Anti-Human VEGF-A Neutralizing Antibody Versus Bevacizumab On A Laser-Induced Choroidal Neovascularization (CNV) Rhesus Monkey Model

Oscar Olvera Montaño,Leopoldo Martin Baiza Duran,Juan De Dios Quintana Hau,Mayra G Quiñonez-Alvarado,Wen Zeng,Li Gong,Patricia Muñoz-Villegas

Comparing The Efficacy Of An Anti-Human VEGF-A Neutralizing Antibody Versus Bevacizumab On A Laser-Induced Choroidal Neovascularization (CNV) Rhesus Monkey Model

2019

Oscar Olvera Montaño
Leopoldo Martin Baiza Duran
Juan De Dios Quintana Hau
Mayra G Quiñonez-Alvarado
Wen Zeng
Li Gong
Patricia Muñoz-Villegas

Purpose To evaluate the efficacy of a therapy on improving characteristics of laser-induced choroidal neovascularization (CNV) via single intravitreal injection of a humanized anti-human VEGF monoclonal antibody (PRO-169) versus bevacizumab in a rhesus monkey model.

Keywords:

Diabetes mellitus
Bevacizumab
Neutralizing antibody
Pharmacology
Choroidal neovascularization
Medicine
VEGF receptors
Ophthalmology
Excretion
Retinal
Adverse effect

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations